The European Journal of Health Economics

, Volume 19, Issue 3, pp 473–481 | Cite as

Authors’ reply to Gandjour: “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”

  • Alexander Kuhlmann
  • J.-Matthias Graf von der Schulenburg

We thank Professor Gandjour for the interest in our article. His comments [1] show that some findings of our study [2] may require a more detailed explanation considering the complexity of the topic: modeling the effects and cost-effectiveness of vaccines including indirect effects. We are grateful for the opportunity to clarify the issues raised by Gandjour. In the following, we will give a point-by-point reply and present results of additional analyses.

Comment 1: quality-adjusted life years (QALY) results

Gandjour argues that the QALY calculation is flawed, since the “number of QALYs gained by the number of life years gained yields a ratio of just 0.56”, which is smaller than the lowest QALY weight in the population (0.59). In addition, PCV13 would prevent pneumococcal infections, which should yield an additional QALY gain. Gandjour therefore concludes that “the number of QALYs gained is underestimated based on the model input data” [1].

Our model predicted substantial benefits of...


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Gandjour, A.: Comment on “Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany”Google Scholar
  2. 2.
    Kuhlmann, A., von der Schulenburg, J.-M.G.: Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany. Eur. J. Health. Econ. 18(3), 273–292 (2017). CrossRefPubMedGoogle Scholar
  3. 3.
    Tregnaghi, M.W., Sáez-Llorens, X., López, P., Abate, H., Smith, E., Pósleman, A., Calvo, A., Wong, D., Cortes-Barbosa, C., Ceballos, A., Tregnaghi, M., Sierra, A., Rodriguez, M., Troitiño, M., Carabajal, C., Falaschi, A., Leandro, A., Castrejón, M.M., Lepetic, A., Lommel, P., Hausdorff, W.P., Borys, D., Ruiz Guiñazú, J., Ortega-Barría, E., Yarzábal, J.P., Schuerman, L.: Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children. A double-blind randomized controlled trial. PLoS Med. 11(6), e1001657 (2014). CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Prymula, R., Peeters, P., Chrobok, V., Kriz, P., Novakova, E., Kaliskova, E., Kohl, I., Lommel, P., Poolman, J., Prieels, J.-P., Schuerman, L.: Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae. A randomised double-blind efficacy study. The Lancet 367(9512), 740–748 (2006). CrossRefGoogle Scholar
  5. 5.
    von Kries, R., Toschke, A.M., Siedler, A.: Population-based nationwide study on invasive pneumococcal infections among children in Germany (1997–2003) (unpublished)Google Scholar
  6. 6.
    van Hoek, A.J., Andrews, N., Waight, P.A., Stowe, J., Gates, P., George, R., Miller, E.: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J. Infect. 65(1), 17–24 (2012). CrossRefPubMedGoogle Scholar
  7. 7.
    Federal Statistical Office of Germany (Statistisches Bundesamt): Diagnosedaten der Krankenhäuser ab 2000 (2013)Google Scholar
  8. 8.
    Melegaro, A., Edmunds, W.J.: Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 22(31–32), 4203–4214 (2004). CrossRefPubMedGoogle Scholar
  9. 9.
    Mangen, M.-J.J., Huijts, S.M., Bonten, M.J.M., de Wit, G.A.: The impact of community-acquired pneumonia on the health-related quality-of-life in elderly. BMC Infect. Dis. 17(1), 208 (2017). CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Mangen, M.-J.J., Rozenbaum, M.H., Huijts, S.M., van Werkhoven, C.H., Postma, D.F., Atwood, M., van Deursen, A.M.M., van der Ende, A., Grobbee, D.E., Sanders, E.A.M., Sato, R., Verheij, T.J.M., Vissink, C.E., Bonten, M.J.M., de Wit, G.A.: Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur. Respir. J. 46(5), 1407–1416 (2015). CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Rozenbaum, M.H., Sanders, E.A.M., van Hoek, A.J., Jansen, A.G.S.C., van der Ende, A., van den Dobbelsteen, G., Rodenburg, G.D., Hak, E., Postma, M.J.: Cost effectiveness of pneumococcal vaccination among Dutch infants. Economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ (Clin. Res. Ed.) 340, 2509 (2010). CrossRefGoogle Scholar
  12. 12.
    Garrison, L.P., Mansley, E.C., Abbott, T.A., Bresnahan, B.W., Hay, J.W., Smeeding, J.: Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR drug cost task force report—part II. Value Health 13(1), 8–13 (2010). CrossRefPubMedGoogle Scholar
  13. 13.
    Garber, A.M.: Chapter 4: advances in cost-effectiveness analysis of health interventions. In: Handbook of Health Economics, vol. 1. Elsevier, Amsterdam, pp. 181–221 (2000)Google Scholar
  14. 14.
    Posner, R.A.: The social costs of monopoly and regulation. J. Political Econ. 83(4), 807–827 (1975)CrossRefGoogle Scholar
  15. 15.
    Black, S.B., Shinefield, H.R., Ling, S., Hansen, J., Fireman, B., Spring, D., Noyes, J., Lewis, E., Ray, P., Lee, J., Hackell, J.: Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21(9), 810–815 (2002). CrossRefPubMedGoogle Scholar
  16. 16.
    Black, S., Shinefield, H., Fireman, B., Lewis, E., Ray, P., Hansen, J.R., Elvin, L., Ensor, K.M., Hackell, J., Siber, G., Malinoski, F., Madore, D., Chang, I., Kohberger, R., Watson, W., Austrian, R., Edwards, K.: Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J. 19(3), 187–195 (2000)CrossRefPubMedGoogle Scholar
  17. 17.
    Palmu, A.A., Jokinen, J., Borys, D., Nieminen, H., Ruokokoski, E., Siira, L., Puumalainen, T., Lommel, P., Hezareh, M., Moreira, M., Schuerman, L., Kilpi, T.M.: Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease. A cluster randomised trial. The Lancet 381(9862), 214–222 (2013). CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Center for Health Economics Research Hannover (CHERH)Leibniz Universität HannoverHanoverGermany

Personalised recommendations